Shire PLC (LON:SHP) had its price objective reduced by Liberum Capital from GBX 4,400 ($57.87) to GBX 4,200 ($55.24) in a research report released on Tuesday, October 24th. Liberum Capital currently has a hold rating on the biopharmaceutical company’s stock.
A number of other analysts have also issued reports on SHP. Goldman Sachs Group, Inc. (The) reissued a conviction-buy rating on shares of Shire PLC in a research report on Tuesday, October 17th. Deutsche Bank AG cut their target price on Shire PLC from GBX 6,000 ($78.92) to GBX 5,700 ($74.97) and set a buy rating on the stock in a research report on Tuesday, September 5th. Jefferies Group LLC reissued a buy rating on shares of Shire PLC in a research report on Tuesday, August 22nd. Morgan Stanley cut their price objective on Shire PLC from GBX 5,800 ($76.29) to GBX 5,700 ($74.97) and set an overweight rating on the stock in a research report on Thursday, October 12th. Finally, Societe Generale reaffirmed a buy rating and set a GBX 7,500 ($98.65) price objective on shares of Shire PLC in a research report on Wednesday, July 12th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of GBX 5,358.82 ($70.48).
Shares of Shire PLC (LON:SHP) traded down GBX 12.50 ($0.16) during trading on Tuesday, hitting GBX 3,534.50 ($46.49). The company had a trading volume of 1,912,090 shares, compared to its average volume of 2,470,000. Shire PLC has a 1 year low of GBX 3,435.50 ($45.19) and a 1 year high of GBX 5,186 ($68.21).
TRADEMARK VIOLATION NOTICE: “Shire PLC (LON:SHP) Given New GBX 4,200 Price Target at Liberum Capital” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/11/liberum-capital-cuts-shire-plc-shp-price-target-to-gbx-4200.html.
In related news, insider Anne Minto acquired 190 shares of the stock in a transaction that occurred on Friday, September 29th. The shares were purchased at an average cost of GBX 3,785 ($49.78) per share, with a total value of £7,191.50 ($9,458.77). Also, insider Flemming Ornskov acquired 8,400 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The shares were bought at an average cost of GBX 3,665 ($48.20) per share, for a total transaction of £307,860 ($404,919.11).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.